Total Funding
3
Total FundingVenture - Series Unknown raised
Growth Score in past quarter
pts
Heat Score 3 in past quarter
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3517680
Laurantis Pharma develops therapeutics for medical niche indications in the dermatology, ophthalmology, and oncology sectors.
Acquired by 

Herantis Pharma
- Henri Huttunen: Chief Scientific Officer & Co-founder
About the Company
Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantis
was formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy.


